Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 93
Filter
1.
Cells ; 10(12)2021 12 02.
Article in English | MEDLINE | ID: mdl-34943913

ABSTRACT

Dendritic spines are small, thin, hair-like protrusions found on the dendritic processes of neurons. They serve as independent compartments providing large amplitudes of Ca2+ signals to achieve synaptic plasticity, provide sites for newer synapses, facilitate learning and memory. One of the common and severe complication of neurodegenerative disease is cognitive impairment, which is said to be closely associated with spine pathologies viz., decreased in spine density, spine length, spine volume, spine size etc. Many treatments targeting neurological diseases have shown to improve the spine structure and distribution. However, concise data on the various modulators of dendritic spines are imperative and a need of the hour. Hence, in this review we made an attempt to consolidate the effects of various pharmacological (cholinergic, glutamatergic, GABAergic, serotonergic, adrenergic, and dopaminergic agents) and non-pharmacological modulators (dietary interventions, enriched environment, yoga and meditation) on dendritic spines structure and functions. These data suggest that both the pharmacological and non-pharmacological modulators produced significant improvement in dendritic spine structure and functions and in turn reversing the pathologies underlying neurodegeneration. Intriguingly, the non-pharmacological approaches have shown to improve intellectual performances both in preclinical and clinical platforms, but still more technology-based evidence needs to be studied. Thus, we conclude that a combination of pharmacological and non-pharmacological intervention may restore cognitive performance synergistically via improving dendritic spine number and functions in various neurological disorders.


Subject(s)
Dendritic Spines/drug effects , Diet , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/drug therapy , Cholinergic Agents/therapeutic use , Cognitive Dysfunction/diet therapy , Cognitive Dysfunction/drug therapy , Cognitive Dysfunction/epidemiology , Cognitive Dysfunction/psychology , Dendritic Spines/pathology , Dendritic Spines/physiology , Excitatory Amino Acid Agents/therapeutic use , GABA Agents/therapeutic use , Humans , Meditation/psychology , Neurodegenerative Diseases/epidemiology , Neurodegenerative Diseases/psychology , Neurons/drug effects , Neurons/physiology , Synapses/drug effects , Synapses/metabolism , Yoga/psychology
2.
Biomolecules ; 11(10)2021 10 04.
Article in English | MEDLINE | ID: mdl-34680088

ABSTRACT

Metabolic syndrome increases the risk of vascular dementia and other neurodegenerative disorders. Recent studies underline that platelets play an important role in linking peripheral with central metabolic and inflammatory mechanisms. In this narrative review, we address the activation of platelets in metabolic syndrome, their effects on neuronal processes and the role of the mediators (e.g., serotonin, platelet-derived growth factor). Emerging evidence shows that nutritional compounds and their metabolites modulate these interactions-specifically, long chain fatty acids, endocannabinoids and phenolic compounds. We reviewed the role of activated platelets in neurovascular processes and nutritional compounds in platelet activation.


Subject(s)
Blood Platelets/metabolism , Metabolic Syndrome/diet therapy , Neurodegenerative Diseases/diet therapy , Nutrients/therapeutic use , Blood Coagulation/drug effects , Endocannabinoids/genetics , Humans , Metabolic Syndrome/blood , Metabolic Syndrome/complications , Metabolic Syndrome/pathology , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/pathology , Platelet Activation/drug effects
3.
Int J Mol Sci ; 22(19)2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34638979

ABSTRACT

Neurodegenerative diseases represent a major public health issue and require better therapeutic management. The treatments developed mainly target neuronal activity. However, an inflammatory component must be considered, and microglia may constitute an important therapeutic target. Given the difficulty in developing molecules that can cross the blood-brain barrier, the use of food-derived molecules may be an interesting therapeutic avenue. Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid (22:6 omega-3), has an inhibitory action on cell death and oxidative stress induced in the microglia. It also acts on the inflammatory activity of microglia. These data obtained in vitro or on animal models are corroborated by clinical trials showing a protective effect of DHA. Whereas DHA crosses the blood-brain barrier, nutritional intake lacks specificity at both the tissue and cellular level. Nanomedicine offers new tools which favor the delivery of DHA at the cerebral level, especially in microglial cells. Because of the biological activities of DHA and the associated nanotargeting techniques, DHA represents a therapeutic molecule of interest for the treatment of neurodegenerative diseases.


Subject(s)
Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Drug Delivery Systems/methods , Microglia/metabolism , Nanoparticles/chemistry , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/metabolism , Protective Agents/administration & dosage , Animals , Apoptosis/drug effects , Blood-Brain Barrier/metabolism , Disease Models, Animal , Humans , Inflammation/diet therapy , Inflammation/drug therapy , Inflammation/metabolism , Neurodegenerative Diseases/diet therapy , Oxidative Stress/drug effects , Treatment Outcome
4.
Biomolecules ; 11(6)2021 05 24.
Article in English | MEDLINE | ID: mdl-34073983

ABSTRACT

Neurodegenerative disorders are a widespread cause of morbidity and mortality worldwide, characterized by neuroinflammation, oxidative stress and neuronal depletion. The broad-spectrum neuroprotective activity of the Mediterranean diet is widely documented, but it is not yet known whether its nutritional and caloric balance can induce a modulation of the endocannabinoid system. In recent decades, many studies have shown how endocannabinoid tone enhancement may be a promising new therapeutic strategy to counteract the main hallmarks of neurodegeneration. From a phylogenetic point of view, the human co-evolution between the endocannabinoid system and dietary habits could play a key role in the pro-homeostatic activity of the Mediterranean lifestyle: this adaptive balance among our ancestors has been compromised by the modern Western diet, resulting in a "clinical endocannabinoid deficiency syndrome". This review aims to evaluate the evidence accumulated in the literature on the neuroprotective, immunomodulatory and antioxidant properties of the Mediterranean diet related to the modulation of the endocannabinoid system, suggesting new prospects for research and clinical interventions against neurodegenerative diseases in light of a nutraceutical paradigm.


Subject(s)
Diet, Mediterranean , Endocannabinoids/metabolism , Neurodegenerative Diseases , Neuroprotection , Humans , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/metabolism
5.
Biomed Pharmacother ; 138: 111511, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33744757

ABSTRACT

Flavonoids are natural plant-derived dietary bioactive compounds having a substantial impact on human health. Morin hydrate is a bioflavonoid mainly obtained from fruits, stem, and leaves of Moraceae family members' plants. Plenty of evidences supported that morin hydrate exerts its beneficial effects against various chronic and life-threatening degenerative diseases. Our current article discloses the recent advances that have been studied to explore the biological/pharmacological properties and molecular mechanisms to better understand the beneficial and multiple health benefits of morin hydrate. Indeed, Morin hydrate exerts free radical scavenging, antioxidant, anti-inflammatory, anti-cancerous, anti-microbial, antidiabetic, anti-arthritis, cardioprotective, neuroprotective, nephroprotective, and hepatoprotective effects. Moreover, morin hydrate exhibits its pharmacological activities by modulating various cellular signaling pathways such as Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-қB), Mitogen-activated protein kinase (MAPK), Janus kinases/ Signal transducer and activator of transcription proteins (JAKs/STATs), Kelch-like ECH-associated protein1/Nuclear erythroid-2-related factor (Keap1/Nrf2), Endoplasmic reticulum (ER), Mitochondrial-mediated apoptosis, Wnt/ß-catenin, and Mechanistic target of rapamycin (mTOR). Most importantly, morin hydrate has the potential to modulate a variety of biological networks. Therefore, it can be predicted that this therapeutically potent compound could serve as a dietary agent for the expansion of human health and might be helpful for the development of the novel drug in the future. However, due to the lack of clinical trials, special human clinical trials are needed to address the effects of morin hydrate on various life-threatening disparities to recommend morin and/or morin-rich foods with other foods or bioactive dietary components, as well as dose-response interaction and safety profile.


Subject(s)
Antioxidants/administration & dosage , Flavonoids/administration & dosage , Phytochemicals/administration & dosage , Animals , Antioxidants/isolation & purification , Diabetes Mellitus/diet therapy , Diabetes Mellitus/metabolism , Flavonoids/isolation & purification , Heart Diseases/diet therapy , Heart Diseases/metabolism , Humans , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/metabolism , Phytochemicals/isolation & purification
6.
Neurochem Int ; 145: 105013, 2021 05.
Article in English | MEDLINE | ID: mdl-33689806

ABSTRACT

Debilitating neuropsychiatric and neurodegenerative conditions are associated with complex multifactorial pathophysiology. Their treatment strategies often only provide symptomatic relief, delaying disease progression without giving a complete cure. Potent and safer treatment alternatives beyond symptomatic relief are sought. Herbal supplements have surely been explored due to their multiple component nature to enhance the effect of western medications. One such well-documented nutraceutical in the ancient Greek, Chinese, and Ayurvedic medicine system known for its various medicinal benefits is Asparagus racemosus. Widely used for its lactogenic properties, A. racemosus is also cited in Ayurveda as a nervine tonic. A. racemosus based nutraceuticals have shown to possess adaptogenic, neuroprotective, antioxidant, anti-inflammatory, and nootropic activity under preclinical and clinical settings without posing significant adverse effects. A. racemosus extracts restore the perturbed neurotransmitters and prevent oxidative neuronal damage. From the available neuropharmacological researches, the physiological actions of A. racemosus can ultimately be directed for either augmentation of cognitive ability or in the management of neurological conditions such as stress, anxiety, depression, epilepsy, Parkinson's, and Alzheimer's disease. The studies focus on the multi-component extract, and the lack of standardization has been a major hurdle in preventing the allotment of reported neuropharmacological activity to one of the phytoconstituent. Herbal standardization of the plant extract based on a specific biomarker can help elucidate the intricate biomolecular pathway and neurocircuitries being involved. This, followed by rigorous standardized clinical trials, fixing dosages, and determining contraindications would facilitate the translation of A. racemosus to a FDA-approved neuromedicine for neurological disorders.


Subject(s)
Asparagus Plant , Dietary Supplements , Mental Disorders/diet therapy , Neurodegenerative Diseases/diet therapy , Phytotherapy/methods , Plant Extracts/administration & dosage , Animals , Antioxidants/administration & dosage , Antioxidants/isolation & purification , Humans , Mental Disorders/pathology , Neurodegenerative Diseases/pathology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Plant Components, Aerial , Plant Extracts/isolation & purification
7.
Mar Drugs ; 19(3)2021 Feb 26.
Article in English | MEDLINE | ID: mdl-33652930

ABSTRACT

Edible marine algae are rich in bioactive compounds and are, therefore, a source of bioavailable proteins, long chain polysaccharides that behave as low-calorie soluble fibers, metabolically necessary minerals, vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae were used primarily as gelling agents and thickeners (phycocolloids) in food and pharmaceutical industries in the last century, but recent research has revealed their potential as a source of useful compounds for the pharmaceutical, medical, and cosmetic industries. The green, red, and brown algae have been shown to have useful therapeutic properties in the prevention and treatment of neurodegenerative diseases: Parkinson, Alzheimer's, and Multiple Sclerosis, and other chronic diseases. In this review are listed and described the main components of a suitable diet for patients with these diseases. In addition, compounds derived from macroalgae and their neurophysiological activities are described.


Subject(s)
Diet , Neurodegenerative Diseases/diet therapy , Seaweed/chemistry , Animals , Humans , Neurodegenerative Diseases/physiopathology , Neurodegenerative Diseases/prevention & control
8.
Neuropediatrics ; 52(2): 126-132, 2021 04.
Article in English | MEDLINE | ID: mdl-33231275

ABSTRACT

TPK deficiency due to TPK1 mutations is a rare neurodegenerative disorder, also known as thiamine metabolism dysfunction syndrome 5 (OMIM no.: 614458). Here, we report a new patient with compound heterozygous TPK1 mutations, of which one has not been described so far. The individual reported here suffered from acute onset encephalopathy, ataxia, muscle hypotonia, and regression of developmental milestones in early infancy, repeatedly triggered by febrile infections. Initiation of high-dose thiamine and magnesium supplementation led to a marked and sustained improvement of alertness, ataxia, and muscle tone within days. Contrary to the described natural history of patients with TPK deficiency, the disease course was favorable under thiamine treatment without deterioration or developmental regression during the follow-up period. TPK deficiency is a severe neurodegenerative disease. This case report demonstrates that this condition is potentially treatable. High-dose thiamine treatment should therefore be initiated immediately after diagnosis or even upon suspicion.


Subject(s)
Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/physiopathology , Thiamin Pyrophosphokinase/deficiency , Thiamin Pyrophosphokinase/genetics , Thiamine/pharmacology , Vitamin B Complex/pharmacology , Child , Dietary Supplements , Humans , Magnesium/administration & dosage , Rare Diseases , Thiamine/administration & dosage , Vitamin B Complex/administration & dosage
9.
Nutrients ; 12(12)2020 Dec 18.
Article in English | MEDLINE | ID: mdl-33353018

ABSTRACT

Functional foods enriched with plant polyphenols and anthocyanins in particular attract special attention due to multiple beneficial bioactive properties of the latter. We evaluated the effects of a grain diet rich in anthocyanins in a mouse model of Alzheimer's disease induced by amyloid-beta (Aß) and a transgenic mouse model of Parkinson's disease (PD) with overexpression of human alpha-synuclein. The mice were kept at a diet that consisted of the wheat grain of near isogenic lines differing in anthocyanin content for five-six months. The anthocyanin-rich diet was safe and possessed positive effects on cognitive function. Anthocyanins prevented deficits in working memory induced by Aß or a long-term grain mono-diet; they partially reversed episodic memory alterations. Both types of grain diets prolonged memory extinction and rescued its facilitation in the PD model. The dynamics of the extinction in the group fed with the anthocyanin-rich wheat was closer to that in a group of wild-type mice given standard chow. The anthocyanin-rich diet reduced alpha-synuclein accumulation and modulated microglial response in the brain of the transgenic mice including the elevated expression of arginase1 that marks M2 microglia. Thus, anthocyanin-rich wheat is suggested as a promising source of functional nutrition at the early stages of neurodegenerative disorders.


Subject(s)
Alzheimer Disease/diet therapy , Anthocyanins/administration & dosage , Functional Food , Parkinson Disease/diet therapy , Triticum/chemistry , Alzheimer Disease/chemically induced , Alzheimer Disease/prevention & control , Amyloid beta-Peptides , Analysis of Variance , Animals , Arginase/metabolism , Avoidance Learning , Disease Models, Animal , Food, Fortified , Male , Maze Learning , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microglia/metabolism , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/prevention & control , Open Field Test , Parkinson Disease/etiology , Parkinson Disease/metabolism , Parkinson Disease/prevention & control , Weight Gain , alpha-Synuclein/metabolism
10.
Int J Mol Sci ; 21(24)2020 Dec 15.
Article in English | MEDLINE | ID: mdl-33333772

ABSTRACT

Neuroinflammation is a physiological response aimed at maintaining the homodynamic balance and providing the body with the fundamental resource of adaptation to endogenous and exogenous stimuli. Although the response is initiated with protective purposes, the effect may be detrimental when not regulated. The physiological control of neuroinflammation is mainly achieved via regulatory mechanisms performed by particular cells of the immune system intimately associated with or within the nervous system and named "non-neuronal cells." In particular, mast cells (within the central nervous system and in the periphery) and microglia (at spinal and supraspinal level) are involved in this control, through a close functional relationship between them and neurons (either centrally, spinal, or peripherally located). Accordingly, neuroinflammation becomes a worsening factor in many disorders whenever the non-neuronal cell supervision is inadequate. It has been shown that the regulation of non-neuronal cells-and therefore the control of neuroinflammation-depends on the local "on demand" synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids. When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries. In these conditions, it has been demonstrated that the increase of endogenous Palmitoylethanolamide-either by decreasing its degradation or exogenous administration-is able to keep neuroinflammation within its physiological limits. In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.


Subject(s)
Amides/administration & dosage , Amides/metabolism , Ethanolamines/administration & dosage , Ethanolamines/metabolism , Inflammation/diet therapy , Nervous System Diseases/drug therapy , Neurodegenerative Diseases/drug therapy , Palmitic Acids/administration & dosage , Palmitic Acids/metabolism , Alzheimer Disease/diet therapy , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Amyotrophic Lateral Sclerosis/diet therapy , Amyotrophic Lateral Sclerosis/drug therapy , Amyotrophic Lateral Sclerosis/metabolism , Animals , Autism Spectrum Disorder/diet therapy , Autism Spectrum Disorder/drug therapy , Autism Spectrum Disorder/metabolism , Endocannabinoids/metabolism , Humans , Inflammation/drug therapy , Inflammation/metabolism , Metabolic Networks and Pathways , Multiple Sclerosis/diet therapy , Multiple Sclerosis/drug therapy , Multiple Sclerosis/metabolism , Nervous System Diseases/diet therapy , Nervous System Diseases/metabolism , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/metabolism , Pain/diet therapy , Pain/drug therapy , Parkinson Disease/drug therapy , Parkinson Disease/metabolism
11.
Nutrients ; 12(12)2020 Dec 12.
Article in English | MEDLINE | ID: mdl-33322743

ABSTRACT

Functional foods such as pomegranate, dates and honey were shown by various previous studies to individually have a neuroprotective effect, especially in neurodegenerative disease such as Alzheimer's disease (AD). In this novel and original study, an 1H NMR spectroscopy tool was used to identify the metabolic neuroprotective mechanism of commercially mixed functional foods (MFF) consisting of pomegranate, dates and honey, in rats injected with amyloid-beta 1-42 (Aß-42). Forty-five male albino Wistar rats were randomly divided into five groups: NC (0.9% normal saline treatment + phosphate buffer solution (PBS) solution injection), Abeta (0.9% normal saline treatment + 0.2 µg/µL Aß-42 injection), MFF (4 mL/kg MFF treatment + PBS solution injection), Abeta-MFF (4 mL/kg MFF treatment + 0.2 µg/µL Aß-42 injection) and Abeta-NAC (150 mg/kg N-acetylcysteine + 0.2 µg/µL Aß-42 injection). Based on the results, the MFF and NAC treatment improved the spatial memory and learning using Y-maze. In the metabolic analysis, a total of 12 metabolites were identified, for which levels changed significantly among the treatment groups. Systematic metabolic pathway analysis found that the MFF and NAC treatments provided a neuroprotective effect in Aß-42 injected rats by improving the acid amino and energy metabolisms. Overall, this finding showed that MFF might serve as a potential neuroprotective functional food for the prevention of AD.


Subject(s)
Amyloid beta-Peptides/administration & dosage , Functional Food , Honey , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diet therapy , Phoeniceae/metabolism , Pomegranate/metabolism , Animals , Disease Models, Animal , Magnetic Resonance Spectroscopy/methods , Male , Metabolomics/methods , Neurodegenerative Diseases/prevention & control , Rats , Rats, Wistar
12.
Prog Brain Res ; 256(1): 189-207, 2020.
Article in English | MEDLINE | ID: mdl-32958212

ABSTRACT

Glaucoma is the most common neurodegenerative cause of irreversible blindness worldwide. Restricted caloric regimens are an attractive approach for delaying the progression of neurodegenerative diseases. Here we review the current literature on the effects of caloric restriction on retinal neurons, under physiological and pathological conditions. We focused on autophagy as one of the mechanisms modulated by restricted caloric regimens and involved in the death of retinal ganglion cells (RGCs) over the course of glaucoma.


Subject(s)
Aging , Autophagy , Caloric Restriction , Glaucoma/diet therapy , Neurodegenerative Diseases/diet therapy , Retinal Neurons , Aging/pathology , Animals , Glaucoma/pathology , Humans , Neurodegenerative Diseases/pathology , Retinal Neurons/pathology , Retinal Neurons/physiology
13.
Int Rev Neurobiol ; 154: 79-110, 2020.
Article in English | MEDLINE | ID: mdl-32739015

ABSTRACT

To meet its high energy demands, the brain mostly utilizes glucose. However, the brain has evolved to exploit additional fuels, such as ketones, especially during prolonged fasting. With aging and neurodegenerative diseases (NDDs), the brain becomes inefficient at utilizing glucose due to changes in glia and neurons that involve glucose transport, glycolytic and Krebs cycle enzyme activities, and insulin signaling. Positron emission tomography and magnetic resonance spectroscopy studies have identified glucose metabolism abnormalities in aging, Alzheimer's disease (AD) and other NDDs in vivo. Despite glucose hypometabolism, brain cells can utilize ketones efficiently, thereby providing a rationale for the development of therapeutic ketogenic interventions in AD and other NDDs. This review compares available ketogenic interventions and discusses the potential of the potent oral Ketone Ester for future therapeutic use in AD and other NDDs characterized by inefficient glucose utilization.


Subject(s)
Aging/metabolism , Brain/metabolism , Diet, Ketogenic , Glucose/metabolism , Insulin/metabolism , Ketone Bodies/metabolism , Neurodegenerative Diseases/metabolism , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/diet therapy , Alzheimer Disease/metabolism , Animals , Humans , Neurodegenerative Diseases/diagnostic imaging , Neurodegenerative Diseases/diet therapy
14.
Adv Exp Med Biol ; 1195: 77-91, 2020.
Article in English | MEDLINE | ID: mdl-32468462

ABSTRACT

Neurodegenerative diseases lead to the death of nerve cells in the brain or the spinal cord. A wide range of diseases are included within the group of neurodegenerative disorders, with the most common ones being dementia, Alzheimer's, and Parkinson's diseases. Millions of older people are suffering from such pathologies. The global increase of life expectancy unavoidably leads to a consequent increase in the number of people who will be at some degree affected by neurodegenerative-related diseases. At this moment, there is no effective therapy or treatment that can reverse the loss of neurons. A growing number of studies highlight the value of the consumption of medical foods, and in particular olive oil, as one of the most important components of the Mediterranean diet. A diet based on extra virgin olive oil seems to contribute toward the lowering of risk of age-related pathologies due to high phenol concentration. The link of a polyphenol found in extra virgin olive oil, namely, tyrosol, with the protein tyrosinase, associated to Parkinson's disease is underlined as a paradigm of affiliation between polyphenols and neurodegenerative disorders.


Subject(s)
Neurodegenerative Diseases/prevention & control , Olive Oil/chemistry , Olive Oil/pharmacology , Polyphenols/chemistry , Polyphenols/pharmacology , Diet, Mediterranean , Humans , Neurodegenerative Diseases/diet therapy , Olive Oil/therapeutic use , Phenylethyl Alcohol/analogs & derivatives , Phenylethyl Alcohol/chemistry , Phenylethyl Alcohol/pharmacology , Phenylethyl Alcohol/therapeutic use , Polyphenols/therapeutic use
15.
J Nutr Biochem ; 82: 108401, 2020 08.
Article in English | MEDLINE | ID: mdl-32454412

ABSTRACT

Honey is a natural product, containing flavonoids and phenolic acids, appreciated for its therapeutic abilities since ancient times. Although the bioactive potential is linked to the composition, that is variable depending on mainly the botanical origin, honey has antioxidant and anti-inflammatory properties. Therefore, honey, administered alone or in combination with conventional therapy, might result useful in the management of chronic diseases that are commonly associated with oxidative stress and inflammation state. Obesity is a metabolic disorder characterized by visceral adiposity. The adipose tissue becomes hypertrophic and undergoes hyperplasia, resulting in a hypoxic environment, oxidative stress and production of pro-inflammatory mediators that can be responsible for other disorders, such as metabolic syndrome and neurodegeneration. Experimental evidence from animals have shown that honey improves glycemic control and lipid profile with consequent protection from endothelial dysfunction and neurodegeneration. The purpose of the present review is to summarize the current literature concerning the beneficial effects of honey in the management of the obesity-related dysfunctions, including neurodegeneration. Based on the key constituents of honey, the paper also highlights polyphenols to be potentially responsible for the health benefits of honey. Further well-designed and controlled studies are necessary to validate these benefits in humans.


Subject(s)
Antioxidants/therapeutic use , Honey , Obesity/diet therapy , Animals , Anti-Inflammatory Agents/therapeutic use , Diabetes Mellitus, Type 2/diet therapy , Flavonoids/chemistry , Glycemic Control/methods , Health Status , Humans , Hydroxybenzoates/chemistry , Hyperplasia/diet therapy , Hypertension/diet therapy , Inflammation/diet therapy , Insulin Resistance , Metabolic Syndrome/diet therapy , Neurodegenerative Diseases/diet therapy , Oxidative Stress/drug effects , Polyphenols/chemistry , Polyphenols/therapeutic use
16.
Expert Rev Neurother ; 20(7): 673-686, 2020 07.
Article in English | MEDLINE | ID: mdl-32459513

ABSTRACT

INTRODUCTION: Age related neurodegenerative disorders affect millions of people around the world. The role of the gut microbiome (GM) in neurodegenerative disorders has been elucidated over the past few years. Dysbiosis of the gut microbiome ultimately results in neurodegeneration. However, the gut microbiome can be modulated to promote neuro-resilience. AREAS COVERED: This review is focused on demonstrating the role of the gut microbiome in host physiology in Parkinson's disease (PD) and other neurodegenerative disorders. We will discuss how the microbiome will impact neurodegeneration in PD, Alzheimer's Disease (AD), Multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and finally discuss how the gut microbiome can be influenced through diet and lifestyle. EXPERT OPINION: Currently, much of the focus has been to study the mechanisms by which the microbiome induces neuroinflammation and neurodegeneration in PD, AD, MS, ALS. In particular, the role of certain dietary flavonoids in regulation of gut microbiome to promote neuro-resilience. Polyphenol prebiotics delivered in combination with probiotics (synbiotics) present an exciting new avenue to harness the microbiome to attenuate immune inflammatory responses which ultimately may influence brain cascades associated with promotion of neurodegeneration across the lifespan.


Subject(s)
Dysbiosis , Gastrointestinal Microbiome , Neurodegenerative Diseases , Probiotics/therapeutic use , Dysbiosis/complications , Dysbiosis/diet therapy , Dysbiosis/microbiology , Humans , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/etiology , Neurodegenerative Diseases/microbiology
17.
Article in English | MEDLINE | ID: mdl-32250234

ABSTRACT

BACKGROUND & OBJECTIVES: In old people, both innate and adaptive immune responses are impaired, thus leading to a condition of systemic inflamm-ageing, even including the involvement of the central nervous system (CNS). AIMS: Here, main mechanisms of the immune ageing and neuro-inflammation will be discussed along with the dietary approaches for the modulation of age related diseases. DISCUSSION: Neuroinflammation is caused by the passage of inflammatory mediators through the brain blood barrier to CNS. Then, in the brain, antigenic stimulation of microglia and/or its activation by peripheral cytokines lead to a robust production of free radicals with another wave of proinflammatory cytokines which, in turn, causes massive neuronal damage. Also, infiltrating T cells [T helper (h) and T cytotoxic cells] contribute to neuronal damage. Additionally, a peripheral imbalance between inflammatory Th17 cells and anti-inflammatory T regulatory cells seems to be prevalent in the aged brain, thus leading to a proinflammatory profile. Alzheimer's disease, Parkinson's disease and multiple sclerosis will be described as typical neurodegenerative diseases. Finally, modulation of the immune response thanks to the anti-oxidant and anti-inflammatory effects exerted by dietary products and nutraceuticals in ageing will be discussed. Special emphasis will be placed on polyunsaturated fatty acids, polyphenols, micronutrients and pre-probiotics and synbiotics. CONCLUSION: Ageing is characterized by an imbalance subversion of the immune system with a condition of inflamm-ageing. Neuroinflammation and neurodegenerative diseases seem to be a central manifestation of a peripheral perturbation of the immune machinery. Dietary products and nutraceuticals may lead to a down-regulation of the oxidative and pro-inflammatory profile in ageing.


Subject(s)
Brain/immunology , Diet, Healthy/methods , Immunosenescence/physiology , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/immunology , T-Lymphocytes/immunology , Adaptive Immunity/physiology , Animals , Brain/metabolism , Central Nervous System/immunology , Central Nervous System/metabolism , Diet/methods , Dietary Supplements , Humans , Immunity, Innate/physiology , Inflammation/diet therapy , Inflammation/immunology , Inflammation/metabolism , Inflammation Mediators/metabolism , Neurodegenerative Diseases/metabolism , T-Lymphocytes/metabolism
18.
Curr Opin Psychiatry ; 33(4): 432-438, 2020 07.
Article in English | MEDLINE | ID: mdl-32149739

ABSTRACT

PURPOSE OF REVIEW: This review summarises the most recent evidence regarding the effects of diet in preventing and reducing age-related cognitive decline and neurodegenerative diseases. RECENT FINDINGS: Recent evidence indicates that nutraceuticals and whole diet approaches may protect against the development of age-related cognitive decline and pathological neurodegeneration. The neuroprotective effects are diverse depending on the nutrient employed and may involve a reduction of neuroinflammation, an activation of the endogenous antioxidant defence system and a modulation of the gut microbiota structure and function. SUMMARY: This review summarises the existing evidence in favour of diet as a viable alternative approach to directly impact cognitive decline and neurodegenerative diseases. The single nutrient (polyphenols, B vitamins, long-chain polyunsaturated fatty acids) versus whole diet approach (Mediterranean diet, Dietary Approaches to Stop Hypertension, MIND, Nordic, ketogenic) is presented and discussed. Potential mechanisms of action underlying the beneficial effects of these diets are also described. Implementation of large-scale preventive interventions based on dietary patterns identified as being beneficial to brain health should be a research and public health priority, ideally in conjunction with other health-promoting lifestyle factors.


Subject(s)
Cognitive Dysfunction/diet therapy , Cognitive Dysfunction/prevention & control , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/prevention & control , Humans
19.
Article in English | MEDLINE | ID: mdl-32151695

ABSTRACT

Ketogenic diet is a low carbohydrate and high fat diet that has been used for over 100 years in the management of childhood refractory epilepsy. More recently, ketogenic diet has been investigated for a number of metabolic, neurodegenerative and neurodevelopmental disorders. In this comprehensive review, we critically examine the potential therapeutic benefits of ketogenic diet and ketogenic agents on neurodegenerative and psychiatric disorders in humans and translationally valid animal models. The preclinical literature provides strong support for the efficacy of ketogenic diet in a variety of diverse animal models of neuropsychiatric disorders. However, the evidence from clinical studies, while encouraging, particularly in Alzheimer's disease, psychotic and autism spectrum disorders, is limited to case studies and small pilot trials. Firm conclusion on the efficacy of ketogenic diet in psychiatric disorders cannot be drawn due to the lack of randomised, controlled clinical trials. The potential mechanisms of action of ketogenic therapy in these disorders with diverse pathophysiology may include energy metabolism, oxidative stress and immune/inflammatory processes. In conclusion, while ketogenic diet and ketogenic substances hold promise pre-clinically in a variety of neurodegenerative and psychiatric disorders, further studies, particularly randomised controlled clinical trials, are warranted to better understand their clinical efficacy and potential side effects.


Subject(s)
Diet, Ketogenic/methods , Disease Models, Animal , Mental Disorders/diet therapy , Mental Disorders/metabolism , Neurodegenerative Diseases/diet therapy , Neurodegenerative Diseases/metabolism , Animals , Clinical Trials as Topic/methods , Diet, Ketogenic/psychology , Energy Metabolism/physiology , Humans , Mental Disorders/psychology , Mice , Neurodegenerative Diseases/psychology
20.
Biochem Soc Trans ; 48(1): 51-59, 2020 02 28.
Article in English | MEDLINE | ID: mdl-32096539

ABSTRACT

Much of the world's prominent and burdensome chronic diseases, such as diabetes, Alzheimer's, and heart disease, are caused by impaired metabolism. By acting as both an efficient fuel and a powerful signalling molecule, the natural ketone body, d-ß-hydroxybutyrate (ßHB), may help circumvent the metabolic malfunctions that aggravate some diseases. Historically, dietary interventions that elevate ßHB production by the liver, such as high-fat diets and partial starvation, have been used to treat chronic disease with varying degrees of success, owing to the potential downsides of such diets. The recent development of an ingestible ßHB monoester provides a new tool to quickly and accurately raise blood ketone concentration, opening a myriad of potential health applications. The ßHB monoester is a salt-free ßHB precursor that yields only the biologically active d-isoform of the metabolite, the pharmacokinetics of which have been studied, as has safety for human consumption in athletes and healthy volunteers. This review describes fundamental concepts of endogenous and exogenous ketone body metabolism, the differences between the ßHB monoester and other exogenous ketones and summarises the disease-specific biochemical and physiological rationales behind its clinical use in diabetes, neurodegenerative diseases, heart failure, sepsis related muscle atrophy, migraine, and epilepsy. We also address the limitations of using the ßHB monoester as an adjunctive nutritional therapy and areas of uncertainty that could guide future research.


Subject(s)
3-Hydroxybutyric Acid/metabolism , 3-Hydroxybutyric Acid/therapeutic use , Diabetes Mellitus/diet therapy , Diet, Ketogenic , Dietary Supplements , Epilepsy/diet therapy , Fasting/metabolism , Heart Failure/diet therapy , Hepatocytes/metabolism , Humans , Neurodegenerative Diseases/diet therapy , Sepsis/diet therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...